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Background: Basement membranes in the walls of cerebral capillaries and arteries form a major lymphatic
drainage pathway for fluid and solutes from the brain. Amyloid-β (Aβ) draining from the brain is deposited in such
perivascular pathways as cerebral amyloid angiopathy (CAA) in Alzheimer's disease (AD). CAA increases in severity
when Aβ is removed from the brain parenchyma by immunotherapy for AD. In this study we investigated the
consequences of immune complexes in artery walls upon drainage of solutes similar to soluble Aβ. We tested the
hypothesis that, following active immunization with ovalbumin, immune complexes form within the walls of
cerebral arteries and impair the perivascular drainage of solutes from the brain. Mice were immunized against
ovalbumin and then challenged by intracerebral microinjection of ovalbumin. Perivascular drainage of solutes was
quantified following intracerebral microinjection of soluble fluorescent 3kDa dextran into the brain at different time
intervals after intracerebral challenge with ovalbumin.
Results: Ovalbumin, IgG and complement C3 co-localized in basement membranes of artery walls 24 hrs after
challenge with antigen; this was associated with significantly reduced drainage of dextran in immunized mice.
Conclusions: Perivascular drainage along artery walls returned to normal by 7 days. These results indicate that
immune complexes form in association with basement membranes of cerebral arteries and interfere transiently
with perivascular drainage of solutes from the brain. Immune complexes formed during immunotherapy for AD
may similarly impair perivascular drainage of soluble Aβ and increase severity of CAA.
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Unlike most other organs in the body, the brain has no
conventional lymphatic drainage. However, experimental
studies using soluble tracers in mice have shown that
solutes injected into the interstitial fluid of the brain par-
enchyma drain along basement membranes in the walls
of capillaries and arteries towards regional lymph nodes
in the neck [1,2]. Following injection into the mouse
striatum, ovalbumin (OVA, 49 kDa), fluorescent dextran* Correspondence: rcn@soton.ac.uk
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reproduction in any medium, provided the or3-10 kDa, and soluble amyloid-β (Aβ) diffuse through
the extracellular spaces of the brain and then enter the
basement membranes of cerebral capillaries and arteries
that act as the lymphatic drainage pathways of the brain
[2]. With age and in Alzheimer's disease (AD), insoluble
fibrillary Aβ is deposited in the walls of cerebral capillar-
ies and arteries as cerebral amyloid angiopathy (CAA)
[3-5]. Initially, Aβ is deposited in intramural vascular
basement membranes that form the lymphatic drainage
pathways of the brain but eventually Aβ may occupy the
whole thickness of the walls of arteries and capillaries
[6-8]. Rupture of amyloid laden vessels is associated with
CAA related intracerebral haemorrhage [9,10].
Levels of soluble Aβ are also raised in the brain in AD
and this correlates with cognitive decline, suggestingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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may be impaired with age and AD [11,12]. Trials of im-
munotherapy for AD in humans were introduced follow-
ing successful studies in transgenic mice showing that
insoluble Aβ plaques were removed from the brain fol-
lowing immunization with Aβ42 [13,14]. However, des-
pite the clearance of Aβ plaques from patients with AD,
active immunization seems to increase, rather than de-
crease, the amount of arterial CAA in both transgenic
mice and humans [15-17]. It appears that Aβ can be
solubilised from plaques but it becomes entrapped in
the perivascular drainage pathways manifesting as an in-
crease in the severity of CAA [18]. The dynamics of the
events resulting in increased CAA following immuno-
therapy are not clear but it could reflect either an in-
creased flow of soluble Aβ out of the brain in the
perivascular drainage pathways, or it may reflect impaired
drainage and elimination of soluble Aβ due to the forma-
tion of Aβ-anti-Aβ immune complexes. In addition, trials
of both active and passive Aβ antibody therapy in patients
with AD have encountered side-effects comprising focal
abnormalities in cerebral white matter on imaging,
suggesting an increasing fluid in the subcortical white
matter, again reflecting failure of fluid drainage from the
brain [19]. The pathophysiology underlying the side-
effects of Aβ immunotherapy are as yet unclear but may
be due in part to the effects of immune complexes
forming in perivascular drainage pathways.
In previously published studies, we showed first that
when OVA is injected into the mouse brain, it drains
rapidly out of the brain along basement membranes in
the walls of cerebral capillaries and arteries [2]. Secondly
we showed that active immunization with OVA followed
by the intracerebral injection of the antigen OVA,
resulted in the formation of immune complexes in the
brain parenchyma associated with a robust inflammatory
response and macrophage activation [20].
In the present study, we first tested the hypothesis that
immune complexes form in the interstitial fluid drainage
pathways the walls of cerebral arteries of OVA-immunized
mice following challenge with the antigen. Second, we
tested the hypothesis that the presence of OVA immune
complexes in cerebral artery walls disrupts the perivascu-
lar lymphatic drainage of soluble tracers from the brain.
Methods
Animals
BALB/c mice were originally obtained from Charles River
(Margate, United Kingdom) and bred and maintained in
local facilities. Animal experiments obtained approval
from the local Committee for Ethics at the University of
Southampton and were performed under Home Office li-
cencing. A total number of 75 mice of 6–10 weeks old
were used in this study.Active immunization
8 week old Balb/c mice were immunized against OVA
by intraperitoneal (i.p.) injection of 50 μg OVA (Sigma-
Aldrich, Dorset, UK) in the presence of Alum (1:1 ratio,
Alum inject, Fisher Thermo, Loughborough, UK). Mice
received a booster injection of 100 μg OVA in saline at
2, 4 and 6 weeks and 3 days before the intracerebral in-
jection of OVA.
Generation of immune complexes
Mice were anaesthetized by intraperitoneal injection of
0.1 ml/5 g body weight Avertin (2,2,2 tribromoethanol in
tertiary amyl alcohol). The scalp was shaved and local
anaesthetic (Lignocaine 5% from Biorex Laboratories
Ltd) was placed in the external auditory meati as mice
were positioned in a stereotaxic frame (Kopf Instru-
ments, Tujunga, CA, USA). 10 mg of OVA was freshly
diluted in 1 ml of saline, and 1μl injected into the stri-
atum (bregma 1 mm anterior, lateral 1.5 mm, 2.5 mm
deep) of OVA-immunized or control non-immunized
mice. Injections were performed over a period of 2 mi-
nutes through a glass micropipette with an injecting tip
of <50 μm (Sigma-Aldrich, Dorset, UK). Tissue was col-
lected at 5 minutes (n=6), 3 h (n=3), 24 h (n=12), or 7
days (n=12) after the injections. For analysis of immune
complex formation, mice were perfused with heparinized
saline and brains immediately frozen in Tissue Tek
OCT (Sakura Finetek Europe B. V., Zoeterwoude, The
Netherlands). Blood samples were taken to assess OVA-
specific antibody titers by ELISA and described before
[20]. The brains were trimmed to isolate coronal blocks
of 7 mm thickness that contained the injection site in
the centre and cut into 10 μm thick coronal sections
on a cryostat. Sections were collected on APES coated
slides for histological examination, quantification
studies and immunocytochemistry.
Sections of brain were stained by immunohistochem-
istry to identify elements characteristic of immune com-
plexes and to study their position in relation to cerebral
vascular basement membranes. Complement was iden-
tified by antibodies against mouse C3, (FITC conjugated
rabbit anti-C3, MP Biomedicals, France), at a dilution of
1:2000. Mouse IgG was identified using FITC labelled F
(ab’)2 fragments of goat anti-mouse IgG (Sigma-Aldrich,
Dorset, UK), at 1:500 dilution. Rabbit anti-OVA (Sigma-
Aldrich, Dorset, UK) was used at a dilution of 1:1000.
Activated macrophages were studied using an F4/80
monoclonal antibody, (AbDserotec, Oxford, UK) at
1:500 dilution.
To assess the distribution of the immune complexes in
relation to the cerebrovascular basement membranes,
simultaneous staining of the laminin component of vas-
cular basement membranes was performed by immuno-
cytochemistry using a pan-laminin polyclonal rabbit
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tion. Smooth muscle cells of the tunica media of arteries
were identified by detecting α-smooth muscle actin
using a mouse monoclonal antibody (Sigma-Aldrich,
Dorset, UK) at 1:4000 dilution.
Injections of fluorescent tracer
At 5 minutes, 24hr and 7 days following the intracere-
bral injections of OVA, fluorescein labeled 3 kDa soluble
lysine fixable dextran (Invitrogen, Paisley, UK) was
injected into the striatum, as described previously [2]
(Figure 1). Dextran was injected at 1 μg/μl in a volume of
0.5 μl, over a period of 2 minutes through a glass micro-
pipette with the injecting tip <50 μm (Sigma-Aldrich,
Dorset, UK) as previously described [2]. Mice were
sacrificed at 5 minutes following injection of the tracer.
Tissue was collected after terminal anaesthesia with
sodium pentobarbitone (250–300 μl intraperitoneally)
and transcardially perfusion with heparinized 0.9% saline
followed by 4% paraformaldehyde in 0.1 M phosphate
buffer pH 7.4. Brains were removed and further fixed by
immersion in 4% paraformaldehyde for 4–6 hours and
placed in 30% sucrose for 48 h for cryoprotection. The
brains were trimmed to form coronal blocks 7 mm thick
with the injection site in the centre. Blocks were then fro-
zen in Tissue Tek OCT (Sakura Finetek Europe B. V.,
Zoeterwoude, The Netherlands) and sectioned in a coronal
plane (10 μm thick) on a cryostat. Sections were collected
on gelatin-coated slides for histological examination, quan-
tification studies and immunocytochemistry.
Secondary antibodies or streptavidin (in the cases
where avidin-biotin complex was used) labeled with
Alexa Fluor 488 or Alexa Fluor 546 fluorochrome
(Invitrogen, Paisley, UK) to enable visualization with a
fluorescence microscope. The specificity of the labelingFigure 1 Schematic demonstrating the temporal sequence of immun
immunized with OVA and then injected with OVA in the striatum at differe
intracerebrally at 5 mins or 24 h or 7 days post-immunization. Mice were ewas controlled by omission of the primary antibody.
Mounted sections were cover slipped using Vectashield
(Vector Labs, Peterborough, UK).
Quantitation of interstitial fluid drainage
Images of 1030 × 1030 pixels per inch were obtained
at ×25 magnification at an SP2 Leica Confocal System
using sequential scanning. Co-localization of fluorescent
markers appeared yellow. The illumination of the speci-
men provided by the SP2 confocal laser scanning micro-
scope used in this study was restricted to a single point
(~ 0.25 μm in diameter by ~ 0.5 μm deep), scanned
across the specimen. By inserting a confocal imaging
aperture into the light path, the resulting image com-
prises mainly in-focus information from the focal plane
whilst the majority of the out-of-focus flare (associated
with conventional microscopy) was eliminated. Thus, a
series of in-focus 1 μm optical sections were acquired
and combined to produce a sharp 3 dimensional image
of the whole specimen.
Co-localization technique
When two spectra for different labels (i.e. double label-
ing) are acquired, two data sets are produced (one for
each fluorochrome). The SP2 Leica software compares
the labeling intensity from the two data sets, voxel by
voxel; if there is no labeling in either corresponding
voxel it appears black, labeling in one but not the other
voxel appears green (or red). Whenever a high intensity
of labeling in both channels is detected, the programme
converts the point to a chosen colour (for images in this
thesis, blue or yellow). To minimize false positives due
to fluorescence detected in both channels (“bleed
through”), sequential rather than simultaneous acquisi-
tion of data sets for each fluorochrome was performed.ization and injection experiments. Wild type BALB/c mice were
nt time points. A soluble fixable fluorescent dextran was then injected
xamined at 5 minutes after injections of dextran.
Carare et al. Acta Neuropathologica Communications 2013, 1:48 Page 4 of 11
http://www.actaneurocomms.org/content/1/1/48The number of blood vessels with dextran in their
walls or in perivascular cells was quantified within
the confocal images, using the KS-400 software on a
Zeiss Image Analysis. Five images were taken for
each section. The area within which the blood ves-
sels were counted in each image was of 391193 μm2.
The number of blood vessels outlined with dextran
was used for graphical and statistical analysis. All
statistical tests were carried out using SPSS 16.0.
Two way ANOVA test with Bonferroni correctionFigure 2 Immune complexes in basement membranes in the walls of
followed by intracerebral challenge with OVA and left in situ for (a) 5 mins
is diffusely in the vicinity of blood vessels stained for laminin (red); there is
(red) is seen distributed diffusely in the perivascular brain parenchyma and
parenchyma. (c) At 24 hours after injection of antigen, a longitudinal sectio
complement (green) with laminin (red) in the basement membranes surrou
present in the brain parenchyma and co-localizes (yellow) with laminin (gre
(green) is distributed circumferentially around blood vessels (red=laminin).
seen in the blood vessel walls. Confocal images: co-localization appears aswas applied and values of p<0.05 were considered
statistically significant. The type of blood vessels was
determined by their diameter and the presence of
smooth muscle actin. Vessels were considered to be
capillaries if their diameter was under 10 μm and if
they lacked smooth muscle actin staining; arteries
were defined by a diameter greater than 10 μm and
by the presence of smooth muscle actin staining in
their walls. Veins were larger than 10 μm in diam-
eter and lacked smooth muscle actin.cerebral capillaries and arteries. Active immunization with OVA was
, (b-d) 24 hours and (e) 7 days. (a) At 5 mins, complement C3 (green)
no co-localization of complement and laminin. (b) At 24 hours, IgG
is co-localized (yellow) with complement C3 (green) in brain
n of an artery in the striatum shows co-localization (yellow) of
nding smooth muscle cells in the tunica media. (d) IgG (red) is
en) in a blood vessel wall at 24 hours. (e) At 7 days, complement C3
Some co-localization of complement C3 and laminin (yellow) is still
a yellow colour. Scale bars = 60 μm.
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Relation of immune complexes to the cerebral
vasculature following intracerebral injection of ovalbumin
in ovalbumin- immunized mice
The immunization protocol has been shown in previous
studies to generate high levels of circulating OVA spe-
cific antibodies, with half maximal binding within dilu-
tions of 1:105 -1:107, demonstrated in a previous related
study [20].
We previously showed that intracerebral injection of
OVA in OVA-immunized mice results in immune com-
plex formation and inflammation around cerebral blood
vessels [20]. In the current study we aimed to investigate
the kinetics and location of the immune complexes in
more detail and to test the hypothesis that the perivas-
cular drainage of solutes is affected under these condi-
tions. To analyze immune complex formation followingFigure 3 Immune complexes. Immune complex formation was analyzed
(green) and OVA (red), b and e) C3 (green) and OVA (red) and c) IgG (gree
Representative of n=3. Scale bar =75 am.intracerebral OVA injection at different time points, we
first stained tissue from non-immunized and OVA im-
munized mice for OVA, IgG, and C3. Laminin was used
to identify the location of the immune complex within
the blood vessel wall (Figure 2). Five minutes and three
hours after its injection in immunized mice, OVA was
diffusely spread in the ipsilateral striatum, corpus
callosum and cortex as described previously [2]. Around
the injection site for OVA, Complement C3 and IgG
were present on both sides of the laminin of capillaries
of OVA immunized mice (Figure 2a). IgG was seen
within the lumen of blood vessels, with little extravasa-
tion in the perivascular space. The staining for C3 was
diffuse and limited only to the injection site, without any
C3 observed in basement membranes. Non-immunized
control mice showed minimal levels of IgG and C3 (data
not shown).at 24 h after intracerebral OVA injection and stained for: a and d) IgG
n), C1q (red) and OVA (blue). Co-localization is shown in yellow.
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fied in the brain in close proximity to the cerebral vascu-
lature and double staining for IgG and laminin revealed
that IgG and complement C3 were present in the paren-
chyma and also co-localized with laminin present in the
walls of blood vessels (Figure 2b-d). Staining for IgG,
OVA, C3 and C1q confirmed the presence of immune
complexes in the parenchyma and their association with
blood vessels (Figure 3). OVA was no longer detectable
in association with the cerebrovascular basement mem-
branes at 7 days (Figure 2e).
Reduced perivascular drainage of dextran tracer in the
presence of immune complexes
Having demonstrated that immune complexes are formed
in the basement membrane, 24 h, but not yet at 5 minutes,
after intracerebral injection of OVA, we next investigated
perivascular drainage in the presence of immune complexes
by co- injecting a fluorescent tracer at 5 minutes, 24 h and
7 days following the intracerebral injection of OVA.
We previously showed that within five minutes of its
injection, fluorescent dextran spreads diffusely and is
found at the basement membranes of cerebral capillaries
of the grey matter [2]. Therefore we used this time pointFigure 4 Perivascular drainage of dextran. (a) Following active immuni
and 5 minutes after the injection of dextran (green), the distribution of dex
capillaries and arteries. The arrow points to an artery with smooth muscle s
after the intracerebral injection of OVA, the dextran injected intracerebrally
vascular laminin (red). (c) In mice actively immunized with OVA, at 7 days a
of blood vessels (arrowhead) and present within cuffs around large blood
after the intracerebral injection of OVA and 24 h after the intracerebral inje
perivascular location (red-laminin). Confocal images: co-localization appearsto test if drainage of dextran is impeded following im-
mune complex formation in the basement membranes
of cerebral blood vessels. In a separate group of mice,
we allowed dextran to drain for 24 h.
Five minutes after OVA injection, we observed a dif-
fuse distribution of the fluorescent tracer dextran in the
extracellular space and within the walls of capillaries and
arteries of OVA immunized mice (Figure 4a). This pat-
tern was similar to non-immunized, control animals
(data not shown). Quantification of the type of vessels
that contained dextran associated with their walls re-
vealed that at 5 minutes after injection of OVA, there
was no difference in the number of dextran positive ar-
teries or capillaries, compared to non-immunized con-
trols (Figure 5a and b). Furthermore, there were no
differences in the number of veins labeled with dextran
between this group and control animals (Figure 5c).
At 24 h after OVA injection, dextran had a reticular
cuff appearance around laminin in the walls of capillaries
and arteries (Figure 4b). Quantification of the number of
blood vessels that contained dextran associated with the
basement membranes revealed no difference in the
number of capillaries with dextran in their walls, com-
pared to non-immunized control mice (Figure 5a). Azation with OVA, at 5 minutes after the intracerebral injection of OVA
tran is diffuse in the extracellular spaces and within the walls of
taining (red). (b) Following active immunization with OVA, at 24 hours
(green) is present within 5 minutes of its injection as cuffs around
fter the intracerebral injection of OVA, dextran (green) is in the walls
vessels (arrow). (d) In mice actively immunized with OVA, at 7 days
ction of dextran (green), the dextran is present in cells within a
as a yellow colour. Scale bars: a, b, d = 100 μm; c = 120 μm.
Figure 5 Quantification of the number of blood vessels labeled
with fluorescent dextran following the formation of immune
complexes. Control (non-immunized) and OVA-immunized mice
where OVA was left intracerebrally for 5 minutes, 24 h, 7 days,
followed by the injection of fluorescent dextran and animals
sacrificed within 5 mins. (a) The number of capillaries in control and
OVA immunized mice, following intracerebral injection of OVA at 5
minutes, 24 h, or 7 days. The number of capillaries labeled with
dextran is significantly lower in immunized animals, analyzed 24 h
after OVA injection, compared to analysis at 5 minutes. (b) The
number of arteries in control and OVA immunized mice, following
intracerebral injection of OVA at 5 minutes, 24 h, or 7 days. The
number of arteries labeled with dextran is significantly lower in OVA
immunized mice where immune complexes were left to form for 24
hours, compared to the control non-immunized group. (c) There is a
significant difference between the number of veins with dextran in
a perivascular location in the OVA immunized mice analyzed at 24 h
or 7 days, compared to control non-immunized mice.
*p≤0.001; **p<0.005.
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ies with dextran in their walls was observed compared
to controls (p=0.003, Figure 5b). We further showed that
dextran positive veins are significantly higher (p<0.001,
Figure 5c) in OVA-immunized mice when analyzed 24 h
after intracerebral OVA injection.
At 7 days after immune complex formation the pat-
tern of distribution of dextran was remarkably different
between the OVA-immunized and non-immunized
groups of mice. In OVA-immunized mice, the diffuse
dextran in the extracellular space was confined only to
the injection site. The injected dextran outlined the
basement membranes of some blood vessels but was
also associated with thick perivascular cellular cuffs
around other blood vessels (Figure 4c). Staining with
smooth muscle actin and subsequent measurement of
the diameter of the blood vessels revealed that dextran
was present in the walls of capillaries and arteries but
the perivascular cuffs with uptake of dextran was
present solely around veins and not around arteries
or capillaries. In addition, we detected an increased
number of F4/80 positive cells in the injection site
(Figure 6b). A statistically significant number of veins
contained dextran in the surrounding F4/80 positive
cells, compared to non-immunized control animals
(p=0.001, Figure 5c), while quantification of the number
of capillaries and arteries that contained dextran in as-
sociation with basement membranes revealed no differ-
ence (Figure 5a and 5b).
Discussion
When OVA is injected into the mouse brain, it diffuses
through the extracellular spaces of the grey matter and
drains out of the brain along basement membranes in
the walls of cerebral capillaries and arteries following the
lymphatic drainage pathways of the brain parenchyma
[2]. Following immunization of mice using OVA as the
antigen, injection of OVA into the brain results in the
formation of immune complexes in the parenchyma and
this stimulates macrophage invasion and/or microglial
activation [20]. The aim of the present paper was to test
the hypotheses that a) following the injection of OVA
into OVA-immunized mice, immune complexes form
within the basement membranes in the walls of cerebral
capillaries and arteries and that b) such intramural im-
mune complexes disrupt perivascular lymphatic drainage
of solutes from the brain. We present evidence that both
these hypotheses have been substantiated.
Location of immune complexes in the walls of
cerebral arteries
The presence of the complement components C1q and
C3, IgG, and OVA was used in the present study as a
marker for immune complex formation [22]. Such
Figure 6 Active immunization with OVA followed by intracerebral challenge with OVA that was then left in situ for 7 days. Immune
complex formation induces expression of F4/80 on perivascular macrophages and microglia and changes the pattern for the diffusion and
elimination of dextran. (a) In non-immunized control mice, dextran (green) outlines the contour of a large blood vessel. Immunofluorescence for
F4/80 reveals no staining. (b) 7 days following immune complex formation, F4/80 staining (red) is seen in the parenchyma and adjacent to blood
vessels. Dextran (green) forms a large cuff around a blood vessel and is closely associated with the staining for F4/80. The yellow staining within
the dextran cuff (inset) indicates co-localization with F4/80. Scale bars = 100 μm.
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bral arteries, co-localizing with laminin in the intramural
basement membranes, 24 hours after the injection of
OVA into the grey matter of mice immunized against
OVA. Co-localization of the components of immune
complexes with laminin was identified by confocal mi-
croscopy using immunocytochemistry.
Immune complexes in the walls of cerebral arteries
disrupt perivascular drainage of solutes from the brain
Normally, when solutes of different molecular weights like
OVA, monomeric soluble Aβ or 3 kDa dextran are in-
jected into the grey matter of the mouse brain, they diffuse
rapidly through the interstitial spaces and can be located
in the basement membranes in the walls of cerebral capil-
laries and arteries within 5 min of injection. In this study,
we tested the hypothesis that immune complexes within
basement membranes would disrupt the perivascular
drainage of solutes. Our results showed disruption of peri-
vascular drainage of dextran 24 hours after the injection
of OVA into OVA-immunized mice and at the same time
that immune complexes were located in vascular base-
ment membranes. The coincidence of immune complexes
in arterial basement membranes and disruption of peri-
vascular drainage of dextran is further emphasized by the
finding that immune complexes were no longer present in
the basement membranes of arteries 7 days after the injec-
tion of OVA in immunized mice.
Effects of inflammation on perivascular drainage
Seven days following the intracerebral injection OVA into
OVA-immunized mice, there was extensive perivenous ac-
cumulation of inflammatory cells in the brain. The inflam-
matory reaction resulted in distortion of distribution of
the dextran tracer injected into the brain. Dextranaccumulated in the enlarged perivenous spaces and was
presumably taken up by activated macrophages. Although
there was a trend for a reduced number of capillaries and
arteries showing dextran in the walls in the 7 day OVA-
immunized animals, it did not reach statistical signifi-
cance. This suggests that the presence of perivenous in-
flammatory cuffs at this time-point does not have a
significant effect on perivascular drainage of solutes along
the walls of capillaries and cerebral arteries.
Perivascular macrophages normally take up tracers
such as dextran and Aβ that are injected into the brain
parenchyma [2,23]. By 24 hours after the injection of
dextran into normal mice, dextran is only present in
perivascular macrophages around arteries in the ipsilat-
eral hemisphere and no dextran is detected within base-
ment membranes in artery walls. In immunized mice
that had formed immune complexes and were examined
24 hours after the injection of dextran, perivascular mac-
rophages had taken up dextran around arteries in the
parenchyma in the vicinity of the injection and around
veins. This suggests that perivascular macrophages play
a key role in clearing solutes from the brain when peri-
vascular drainage is disrupted.
Implications for Aβ immunotherapy in Alzheimer’s
disease
Following Aβ immunization in AD, there is an increase
in Aβ42 in capillary and artery walls [18,24,25]. Aβ40 is
usually the predominant amyloid in vessel walls and
Aβ42 is detected mainly in parenchymal plaques. In-
creased amounts of Aβ42 in vessel walls following
immunization appear to be the result of solubilization of
the parenchymal plaques [18,24] allowing more Aβ42 to
reach the drainage channels in capillary and artery walls,
accompanied by vasogenic oedema [19].
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the brains of immunized humans against Aβ. However,
it is possible that Aβ solubilized from plaques may en-
counter Aβ- specific antibodies generated in the process
of immunotherapy in the walls of cerebral blood vessels.
High levels of complement have been reported in trans-
genic mice that harbour Aβ mutations and that comple-
ment co-localizes with the microvascular Aβ [26].
Increased levels of C3 were also found to associate with
increased haemorrhages following experimental im-
munotherapy [27-30], and de-glycosylated antibodies,
with reduced complement binding activity, show re-
duced haemorrhages in an experimental mouse model,
suggesting an important role of the effector function of
therapeutic antibodies in the development of these side
effects [31]. It has been reported that, following im-
munotherapy with Aβ in mouse models, small amounts
of anti-Aβ antibodies enter the brain and form immune
complexes that are cleared from the brain into the blood
via the neonatal Fc receptors present ubiquitously in the
endothelia [32]. In our model, in wild type mice, we ob-
served accumulation of OVA in perivascular macro-
phages, arguing against the removal of immune
complexes via this receptor. A possible explanation may
be due to the high antibody titers in our model, leading
to higher levels of immune complexes (excess IgG) that
saturate efflux mechanisms via FcRn.C3
Imm
Com
IgG
Antigen
Drainage of solub
dextran tracer is bloc
by immune complex
Capillary
BM
BM – Basement Membrane
a
b
Figure 7 Diagram to illustrate the possible mechanism by which imm
(a), soluble antigen in the extracellular space interacts with IgG extravasated f
of complement C3. The immune complexes formed block the arterial baseme
the drainage of a soluble tracer (dextran) is blocked by the presence of immu
is taken up by activated macrophages and microglia surrounding the blood v
by FcR ligation following immune complex formation, which initiates an infla
macrophages take up dextran by phagocytosis, thereby indirectly impeding eThe risk of intracerebral haemorrhage may increase if
immune complexes are formed in the basement mem-
branes of capillaries and arteries affected by CAA, as the
wall is already structurally weak from the deposition of Aβ
and is predisposed to aneurysm and rupture [9,21,33]. Re-
cently it has been shown that active immunotherapy using
Aβ derivatives and alum in adult but not old Tg2576 mice
results in a reduction of Aβ burden, without worsening of
CAA or inducing microhaemmorhages [34]. In the light
of the findings of our study, if blood vessels are still un-
affected by the morphological changes associated with
senescence and deposition of Aβ, they may accommodate
the drainage of the Aβ solubilized from plaques, without
rupturing the vascular wall. This is particularly important
in the light of new immunization protocols that are ad-
ministered early, before AD pathology is advanced [35,36].
Conclusions
Our results demonstrate that immune complexes that
are present within the walls of arteries interfere with
perivascular drainage of solutes. Inflammation associated
with the presence of immune complexes results in a
sequestering of solutes within inflammatory cells. We
do not know whether immune complexes form in
the extracellular spaces of the brain and then drain via
perivascular routes, or whether they form within the ar-
terial basement membranes (Figure 7). It remains to beune 
plex
Immune complex in 
Basement membrane
Xle ked es
Artery
une complexes disrupt the perivascular drainage of solutes. In
rom the circulation resulting in immune complex formation and fixation
nt membranes that represent the perivascular drainage pathway. In (b),
ne complexes in the arterial basement membranes. Alternatively, dextran
essels. We previously showed that macrophages/microglia are activated
mmatory in response surrounding the blood vessels (veins). The activated
limination of solutes from the brain.
Carare et al. Acta Neuropathologica Communications 2013, 1:48 Page 10 of 11
http://www.actaneurocomms.org/content/1/1/48clarified to what extent immune complexes are formed
after immunization with Aβ and the proportion of capil-
laries and arteries that remain functional to allow the
drainage of solubilized Aβ and other metabolites. Future
prophylactic and therapeutic strategies in ageing and
CAA will aim to test chaperone molecules that may fa-
cilitate drainage along cerebrovascular basement mem-
branes even if immune complexes reside in them.
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